Brief: Cereno Reports Favorable Safety, Tolerability Of CS1 Treatment In PAH

Cereno Scientific AB

31/03/2026 06:39

March 31 (Reuters) - Cereno Scientific AB CRNOSb.ST:

REPORTS FAVORABLE SAFETY AND TOLERABILITY AFTER 12 MONTHS OF CS1 TREATMENT IN PAH FROM THE EXPANDED ACCESS PROGRAM

CS1 WELL TOLERATED OVER 12 MONTHS WITH NO UNEXPECTED SAFETY CONCERNS OR DRUG-RELATED DISCONTINUATIONS

FURTHER ANALYSES FROM EAP INCLUDING IMAGING SUB-STUDY TO BE COMMUNICATED DURING Q2 2026

Source text: ID:nWkr9SjV4

Further company coverage: [CRNOSb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))